While July was quiet, August brought brisk business to the world of pharmaceutical M&A.
During the latter month, two of the industry's biggest names announced multi-billion dollar deals, with healthcare giant Johnson & Johnson (NYSE: JNJ) throwing $6.5 billion at Momenta Pharmaceuticals and French pharma major Sanofi (Euronext: SAN) spending nearly $3.7 billion on Principia Biopharma.
Our table below details the deals done over the two-month period:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze